December 2022: Japan Registry Update

A notice regarding the renovation work of transferring the registration information was posted on Japan Registry of Clinical Trials (jRCT) on December 09, 2022 :

According to the notice, the renovation work would be done to transfer the registration information from the registries, Japan Medical Association Clinical Trial Registry System (JMACCT-CTR) and Japan Pharmaceutical Information Center Clinical Trial Information (JapicCTI) to the Clinical Research Submission and Publication System of jRCT. This renovation work to transfer the studies will be carried out to improve the search of Clinical trials and studies on jRCT. During this period, no updates can be made to the clinical trial information registered on JMACCT-CTR and JapicCTI.

Please click here to go to the original update.

October 2022: WHO Open Consultation for Harmonization of Clinical Trial Results

The World Health Organization (WHO) has released a consultation page to solicit feedback from stakeholders – including researchers, patients, journal editors, funders, industry sponsors, and regulators. The aim is to promote harmonization of minimum data elements for reporting study results in trial registries.

It accommodates the submission of responses on a scale of 1-5 based on the importance of collecting data for various data elements. It includes the following sections – Trial status and dates, Participant flow, Baseline data, Outcome measures and their results including statistical analysis, Adverse events, and public disclosure of study documents.

The deadline for submitting feedback is 11 November 2022.

September 2022: Japan Registry Update

A notice regarding the discontinuation of the Clinical Trial Promotion Center was posted on Japan Medical Association Center for Clinical Trials – Clinical Trial Registry (JMACCT-CTR) on September 08, 2022, and the updates are summarised below:

  • The JMACCT-CTR will be abolished and the eTraining Center for Clinical Trials will be discontinued on January 31, 2023. It is recommended to download various certificates and browsing materials by January 31, 2023.
  • The data extraction from the JMACCT-CTR system is not possible and there is no alternative site.
  • The login to the system will be disabled after March 01, 2023.
  • The newsletter, meeting announcements and other associated operations will be discontinued after March 31, 2023.
  • New registrations on JMACCT-CTR will be accepted only until September 30, 2022.
  • Information updates on JMACCT-CTR will be accepted only until November 30, 2022.

Please click here to go to the original update.

September 2022: Thai Clinical Trials Registry (TCTR) Update

The Thai Clinical Trials Registry (TCTR) recently launched its advanced search function with additional search options or tabs for better navigation of clinical studies registered on the registry.

The search option is now capable to analyse the studies based on recruitment status, inclusion criteria, study type, study phase, summary results, deidentified individual participants-level data sharing, sponsor, and first posted date.

The registrant is responsible for the accuracy and the updated data of the trial information on the registry.

August 2022: Japan Registry Update

A notice regarding the discontinuation of the Clinical Trial Promotion Center was posted on Japan Medical Association Center for Clinical Trials – Clinical Trial Registry (JMACCT-CTR) on August 23, 2022:

On August 23, 2022, at the 6th meeting of the Board of Directors of the Japan Medical Association, it was decided to abolish the Clinical Trial Promotion Center and reorganize its operations. The registration data will be transferred from JMACCT-CTR to the Japan Registry of Clinical Trials (jRCT) before January 31, 2023.

Please click here to go to the original update.

July 2022: China Registry Update

Suspension of Supplementary Registration

From July 05, 2022, the Chinese Clinical Trial Registry (ChiCTR) has suspended supplementary registration of Clinical Trials.

Supplementary registration is defined as the registration done after the first case of candidate is recruited.

There have been no other changes made to the information available for supplementary registrations on the ChiCTR website.

July 2022: Japan Registry Update

A notice regarding ‘Preparation of Change notifications’ is posted on Japan Registry Clinical Trial (jRCT) on July 08, 2022:

According to the notice, for Specific and Non-specific clinical research, it is now possible to make minor changes and non-notification changes to the record. Minor changes and non-notification changes to items of the record can be published in advance, only when the edited items are not duplicated due to these changes.

Please click here to go to the original update.

June 2022: Australia and New Zealand Update

An update posted on the Australia New Zealand Clinical Trial Registry (ANZCTR) informs users that a series of short, detailed videos for researchers or any authorized representatives explaining steps of registering a new trial on the ANZCTR are now available on their website.

The series feature instructional videos demonstrating how to report interventions, outcome measures, and data sharing statement fields while filling out a registration form on the website.

More information can be found here.

June 2022: Netherlands Update

Netherlands Trial Register (NTR) No Longer Available

As per an update posted on Central Committee on Research Involving Human Subjects (CCMO) website on June 24, 2022, the NTR is no longer available. The National Trial Register, in which the CCMO register and the NTR will be merged, is not yet ready for use.

Guidelines provided to researchers for the time being are as below:

  • For ongoing investigations that were already reported to the NTR: The data as registered in NTR are automatically included in the International Clinical Trial Registry Platform (ICTRP) and can be consulted on the  ICTRP Search Portal. The researcher thus still meets the requirement of prospective registration as required by the International Committee of Medical Journal Editors (ICMJE) for publication in scientific journals. Unfortunately, the data can no longer be edited. If adjustment of the data is nevertheless necessary, the research will have to be registered again with another recognized register, see below. A reference to the trail ID of NTR must be included.
  • For registering new trials: New studies can be registered on any WHO recognized registers, such as The full list of recognized registries can be found at Primary registries in the WHO registry network.

As soon as this situation changes, the CCMO will inform researchers. Click here for more information.

April 2022: Netherlands Update

Performance studies on in vitro diagnostics (IVDR)

On 26 May 2022, the EU Regulation on Medical Devices for In Vitro Diagnostics, also known as the In Vitro Diagnostics Regulation (EU no 2017/746, IVDR) will come into effect. The IVDR contains specific rules for the submission, assessment and execution of performance studies on in vitro diagnostics, IVDs. On the CCMO website, the necessary information for researchers is available on the special theme page Performance studies for in vitro diagnostics as of 29 April 2022.

Performance studies on in vitro diagnostics are divided into different legal frameworks. These frameworks are described in Legislation and regulations, guidelines and standards .

For information about the submission and content of the research file, please visit the Primary Submission and Standard Research File page.

On the During and after page, you will find information about what to report during and after an IVD performance study.


  • The client must submit a report on the performance study within one year of the end of the performance study. The requirements for the report are set out in Annex XIII of the IVDR (section 2.3.3 of Section A).
  • The sponsor must submit a layperson summary of results within one year of the conclusion of the performance study.
  • If it is not feasible for scientific reasons to submit the report and the lay summary within one year of the end of the performance study, the client must have laid down a different period with reasons in the plan for the performance study (Clinical Performance Study Plan — CPSP). The review committee assesses whether the extension of the term is justified.
  • If the performance study been suspended or terminated prematurely, a period of three months instead of one year applies for submitting the report and the lay summary.
  • If the performance study been suspended and restarted within three months, the client does not have to submit a report and a lay summary.

Once Eudamed is operational, the results of the performance study must be uploaded in Eudamed and the report and the lay summary will be made public via Eudamed (IVDR Article 73.7).

Information about starting an appeal or objection procedure against a decision by the accredited MREC or the CCMO can be found under  Appeals and objections.